Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
March 08, 2024 04:00 ET
|
Galimedix Therapeutics, Inc.
GAL-201 specifically targets and binds to misfolded Aβ monomers, preventing their aggregation to toxic Aβ oligomers and protofibrilsAs a consequence, consistent beneficial effects have been...
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
March 29, 2023 08:00 ET
|
Galimedix Therapeutics, Inc.
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...
Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab
October 29, 2019 08:00 ET
|
Galimedix Therapeutics, Inc.
KENSINGTON, Md., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain,...
Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit
October 21, 2019 09:45 ET
|
Galimedix Therapeutics, Inc.
KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
Galimedix Therapeutics, Inc. Appoints Recognized Industry Veteran, Alexander Gebauer, M.D., Ph.D., as Executive Chairman
October 21, 2019 08:30 ET
|
Galimedix Therapeutics, Inc.
KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting
October 08, 2019 09:35 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., which is developing new solutions for neurodegenerative diseases of the retina and the brain,...
Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models
May 08, 2019 08:00 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, May 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data...
Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors
May 06, 2019 07:00 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announces the...
Galimedix Therapeutics to Present at the BIO CEO & Investor Conference
February 11, 2019 08:30 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced...
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
February 06, 2019 09:35 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an...